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CONTROLLING YOUR DNA: PRIVACY CONCERNS IN
GENOMIC TESTING AND THE UNCERTAINTY OF
FEDERAL REGULATION AND LEGISLATION
Sarah Washburn *

I. INTRODUCTION
The headlines In November 2013, the United States Food and
Drug Administration (FDA) issued a “cease and desist” order to the leading direct-to-consumer (DTC) genetic testing company 23andMe.1 In the
warning letter, the FDA cited concerns about the public health consequences of inaccurate test results and drastic measures patients could take
due to a false positive or false negative test result.2 Though 23andMe has
temporarily halted access to health-related genetic testing while it complies with the FDA’s regulatory review process, they remain committed to
ensuring consumers have direct access to their health information.3
23andMe is one of many genetic testing companies with the belief that
consumers have the right to access their genetic information and that this
information can help people live longer, healthier lives.4 Open access to
* J.D. Candidate, DePaul University College of Law, 2016; B.S., Physics, DePaul University, 2010. I will
begin my practice in patent law this Fall at Sughrue Mion in Washington D.C. I would like to thank
Professor Josh Sarnoff for his comments and guidance in writing this Comment. I would also like to thank
Mike and Jane Washburn for their continuous support and encouragement.
1
Nancy Fliesler, Direct-to-consumer genetic testing: a case of potential harm, VECTOR (May 5, 2014),
http://vectorblog.org/2014/05/direct-to-consumer-genetic-testing-a-case-of-potential-harm/.
2
U.S. Food and Drug Administration, 23andMe, Inc. 11/22/13, INSPECTIONS, COMPLIANCE,
ENFORCEMENT,
AND
CRIMINAL
INVESTIGATIONS,
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm [hereinafter Warning Letter]. It should be noted that the warning letter points out that the FDA has been diligently working
to help 23andMe comply with regulatory requirements regarding safety and effectiveness and obtain marketing authorization but 23andMe has failed to complete the necessary studies and provide additional information requested by the FDA. Id. According to the letter, 23andMe has failed to even communicate
with the FDA since May, six months prior to the issuance of the warning letter. Id.
3
Anne Wojcicki, An Update Regarding The FDA’s Letter to 23andMe, 23ANDMEBLOG (Nov. 26, 2013),
http://blog.23andme.com/news/an-update-regarding-the-fdas-letter-to-23andme/.
4
Id. Unfortunately many of these companies are no longer pure DTC companies. That is, many of these
companies now require physician involvement in order for the consumer to obtain their genetic infor-
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genetic information will not only give individuals control over their health,
but the research that flows from public genetic information will lead to a
healthier society as a whole. Over-reaching regulators and over burdensome regulations will hinder that goal and inhibit potential scientific progress from free and accessible genetic information.
This Comment explores current regulation and proposed legislation within the field of genomic testing at both the federal and state level.
It will also explore how such regulation and legislation affects the personalized medicine landscape for both the individual and the American public.
I argue for a comprehensive regulatory plan that protects the privacy of
genetic testing consumers without hindering an individual’s access to their
own genetic information, as well as the public accessibility of genetic information for the purposes of scientific and medical advancement. Part II
provides an overview on the science of genetics, genomic sequencing, and
the current state of personalized medicine, including the explosion in popularity of direct-to-consumer genetic services. Part III explores the current
regulatory landscape of DTC genomic testing and access to genomic information for research purposes on both the state and federal level. I then
argue that federal legislators and the FDA should assume a limited role in
the control of genomic information obtained through open and voluntary
consent as to foster innovation and the continued development of personalized medicine.
II. BACKGROUND
Throughout the last Genetic testing involves analyzing DNA,
RNA, chromosomes, and proteins to detect minute variations that may be
connected to various diseases and other health related issues.5 A genetic
test can identify the carrier status for inherited disorders and make predictions about disease risk and medication response.6 Genetic testing has the
potential to be a powerful healthcare tool, but because the basic science
behind it is widely misunderstood, its potential may be quashed through
overzealous regulation or legislation based on unfounded fears. Under-

mation. These companies include Pathway Genomics, Gene by Gene, and GeneDx, just to name a few.
With 23andMe temporarily halting its health-related genetic testing services to consumers in 2013, no pure
DTC companies currently exist. See infra note 84.
5
Jessica Elizabeth Palmer, Genetic Gatekeepers: Regulating Direct-to-Consumer Genomic Services in an
Era of Participatory Medicine, 67 FOOD DRUG L.J. 475, 478 (2012).
6
Id. at 476.
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standing the science of genetic testing is necessary to recognize both the
benefits of and limitations to this probabilistic science.7
The Genome
A gene is the basic unit of heredity.8 Genes are made up of deoxyribonucleic acid (DNA) and serve as instructions for making functional
molecules such as ribonucleic acid (RNA) and proteins.9 Proteins have
many functions within the body including performing chemical reactions
and forming the cell’s structural components, but they cannot copy themselves.10 When a cell needs more proteins, it uses the manufacturing instructions coded in DNA.11 The DNA code of a gene is made up of a sequence of individual DNA building blocks, labeled A (adenine), T
(thymine), C (cytosine) and G (guanine) – collectively called nucleotides.12 The sequence of nucleotides within a gene gives the cell instructions on how to manufacture the necessary protein.13 Genes can vary in
size from a few hundred DNA bases to more than 2 million bases.14 Genes
are packaged tightly into structures called chromosomes.15 Every cell in
the body contains a full set of chromosomes in the nucleus of the cell.16 A
complete set of genes is called a genome.17 The human genome contains
approximately 21,000 genes with three billion pairs of nucleotides.18
While any two individuals’ DNA are 99.9% identical, the variations within
the remaining 0.1% are responsible for the diversity among human be7
Genomic testing is a probabilistic science as compared to a deterministic science. Id. That is, a genetic
test merely describes the probability of a certain disease risk or medicine response. “Reduced risk is not
inconsistent with disease incidence.” Kathryn Schleckser, Physician Participation in Direct-to-Consumer
Genetic Testing: Pragmatism or Paternalism?, 26 HARV. J. LAW & TEC 695, 713-14 (2013). An individual
shown to have a decreased risk for a certain type of cancer may nevertheless develop that cancer. Id. That
does not call into question the validity of the genetic test. Id.
8
U.S. Nat’l Library of Medicine, What is a gene?, GENETICS HOME REFERENCE,
http://ghr.nlm.nih.gov/handbook/basics/gene (Jan. 11, 2016).
9
Nat’l Institute of General Medical Sciences, Chapter 1: How Genes Work, THE NEW GENETICS,
http://publications.nigms.nih.gov/thenewgenetics/chapter1.html (June 9, 2011).
10
Id.
11
Id.
12
Id.
13
Id.
14
What is a gene?, supra note 8.
15
Chapter 1: How Genes Work, supra note 9.
16
Id. Every cell normally contains 23 pairs of chromosomes, giving a total of 46 chromosomes per cell.
U.S. Nat’l Library of Medicine, How many chromosomes do people have?, GENETICS HOME REFERENCE,
http://ghr.nlm.nih.gov/handbook/basics/howmanychromosomes (Feb. 23, 2015). Eggs, sperm, and red
bloods cells are the exception. Chapter 1: How Genes Work, supra note 9.
17
Palmer, supra note 5, at 478.
18
Id.
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ings.19 Although these gene variations are what make each person unique,
certain gene variants are associated with specific diseases and conditions.20
Genomic Medicine
Genetic tests involve the analysis of DNA, RNA, chromosomes, or
proteins in order to detect variations related to health and disease.21 Early
advances in genetic medicine involved identification of disorders caused
by inherited mutations in single genes such as cystic fibrosis, sickle-cell
anemia, and Huntington’s disease.22 Huntington’s disease is a highly penetrant disorder, meaning that almost all individuals with the mutated gene
will eventually develop the disease.23 Thus, a genetic test for Huntington’s
disease is highly predictive.24 Other disorders, such as cystic fibrosis, are
significantly less penetrant.25 The presence of a mutated gene simply
means that there is a possibility of developing a certain disease, but that
possibility is dependent on other factors as well including the environment
and family history.26
Some of the most common diseases are more complex and are not
expressed by a mutation in a single gene.27 Disorders such as heart disease, obesity, addiction, and diabetes are influenced by a complex interplay of genetic and environmental factors.28 To identify the genetic basis
for complex common diseases, genetic researchers began to study single
nucleotide polymorphism (SNPs).29 The most common form of genetic
variation between individuals, SNPs occur about once every 1,000 base
pairs.30 SNPs are the 0.1% of base pairs in the genetic code that differ in
each individual.31 SNPs are only classified as such if the variation occurs

19

Id.
Nat’l Human Genome Research Institute, Regulation of Genetic Tests, National Institutes of Health,
http://www.genome.gov/10002335 (Sept. 2, 2014).
21
Palmer, supra note 5, at 478; Regulation of Genetic Tests, supra note 20.
22
Palmer, supra note 5, at 478.
23
Id.
24
Id.
25
Id.
26
Id.
27
Id.
28
Palmer, supra note 5, at 478.
29
In the scientific community, the acronym “SNPs” is colloquially pronounced “snips”. U.S. Nat’l Library
of Medicine, What are single nucleotide polymorephisms (SNPs)?, GENETIC HOME REFERENCE, (January
4, 2016), http://ghr.nlm.nih.gov/handbook/genomicresearch/snp.; Palmer, supra note 5, at 479.
30
Jeffrey Perkel, SNP genotyping: six technologies that keyed a revolution, 5 NATURE METHODS 447
(2008), http://www.nature.com/nmeth/journal/v5/n5/full/nmeth0508-447.html.
31
Palmer, supra note 5, at 479.
20
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in 1% or more of the population; otherwise the variation is a mutation.32
SNPs can serve as landmarks in the search for genes associated with disease, drug response, and observable traits.33 Because a SNP-based screen
can capture most of the genetic variation between individuals, comparing
SNP data from many participants allows researchers to uncover small statistical associations between SNPs and various health conditions.34 More
than a thousand genetic variants linked to common disorders have been
identified in recent years.35
Even though SNPs make up only about one percent of the human
genome, SNP-based testing can capture most genetic variation among individuals.36 Genetic tests are used to detect gene variants associated with a
specific disease or condition.37 In the clinical setting, genetic tests can be
used to determine the genetic cause of a disease, confirm a suspected diagnosis, predict future illness, detect the likelihood of passing on a gene mutation, and predict response to therapy.38 A number of tests have been developed to perform complex analyses of multiple genes for chronic
diseases such as heart disease and cancer, or to determine a patient’s risk
of cancer reoccurrence.39 Genetic tests are also used to screen newborns,
fetuses, or embryos used in in vitro fertilization for genetic defects.40
They also have non-clinical uses such as paternity testing and forensics.41
Sequencing is the process of determining the exact order of the
base pairs in a segment of DNA.42 Whole genome sequencing refers to the
sequencing of the entire complement of DNA in an individual.43 Unlike
SNP genotyping, which captures less than 0.1% of the genome, full genome sequencing is the complete DNA sequence of an individual.44 Various techniques are utilized in whole genome sequencing including bacterial artificial chromosome (BAC) based sequencing and more recently next32

Perkel, supra note 30.
Id.
34
Palmer, supra note 5, at 479–80.
35
Id.
36
Id.
37
Regulation of Genetic Tests, supra note 20.
38
Id.
39
Id.
40
Id.
41
Id.
42
Illumina
Sequencing
Methods,
ILLUMINA.COM
http://applications.illumina.com/applications/sequencing.html; Nat’l Human Genome Research Institute,
The Human Genome Project Completion: Frequently Asked Questions, NATIONAL INSTITUTES OF HEALTH,
(Oct. 30, 2010), http://www.genome.gov/11006943.
43
Id.
44
Id.
33
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generation sequencing (NGS).45 BAC-based sequencing involves cloning
fragmented pieces of DNA in bacteria, amplifying the DNA.46 The BAC
clones are then cut into still smaller fragments and loaded into a sequencer.47 Computational methods are used to reassemble these short sequences
into the entire sequence representing the human DNA.48 Recent advances
in technology led to next-generation sequencing, enabling more rapid sequencing or larger stretches of DNA base pairs spanning entire genomes.49
NGS involves identifying bases of a small fragment of DNA from signals
emitted as each fragment is resynthesized using a known reference genome.50 This process is extended across millions of reactions in parallel.51
Current Research
The Human Genome Project was a joint venture between the National Institutes of Health (NIH) and the Department of Energy, along with
international partners, to sequence all 3 billion base pairs in the human genome.52 The Project’s goal was to provide researchers with the tools to
understand the genetic factors in human disease, paving the way for new
strategies in diagnosis, treatment and prevention.53 The completed human
sequence is a sort of map, a resource providing a set of detailed information about the structure, organization, and function of the complete set
of human genes.54 All data generated by the Human Genome Project was
made available on the Internet, serving to accelerate the pace of medical
discovery around the world.55 To date, the Project has fueled the discovery of more than 1,800 disease genes, and at least 350 biotechnology-

45

Nat’l Human Genome Research Institute, supra note 20; Illumina, An Introduction to Next-Generation
Sequencing
Technology,
ILLUMINA.COM,
(October
16,
2013),
http://www.illumina.com/content/dam/illuminamarketing/documents/products/illumina_sequencing_introduction.pdf.
46
Id.
47
Id.
48
Id.
49
Id.
50
Illumina, supra note 45 at 4.
51
Id.
52
See generally, Nat’l Human Genome Research Institute, www.genome.gov; Human Genome Project,
www.report.nih.gov.
53
Human Genome Project, www.report.nih.gov.
54
Nat’l Human Genome Research Institute, An Overview of the Human Genome Project, NATIONAL
INSTITUTES OF HEALTH, (Nov. 8, 2012), http://www.genome.gov/12011238.
55
Id.
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based products resulting from the Human Genome Project are currently in
clinical trials.56
The Personal Genome Project was founded in 2005 and is dedicated to creating public genome, health, and trait data.57 While the Human
Genome Project used only one anonymous individual for 70% of the final
sequence and a number of different individuals for the remaining 30%, the
Personal Genome Project aims to recruit as many as 100,000 individuals to
contribute genomic sequence data, tissues, and extensive environmental,
trait and other information to a publicly accessible and identifiable research database.58
There are currently more than 2,000 genetic tests for various human conditions.59 These tests enable patients to learn their genetic risks
for disease and also help healthcare professionals to diagnose disease.60
Having the complete sequence of the human genome is like having an instruction manual to the human body.61 The more researchers study this
manual, the better they can understand human health and disease.62 A
deeper understanding of disease at the genomic level will lead to a new
generation of targeted interventions, including highly effective pharmaceuticals with fewer side effects.63
The Human Genome Project was a thirteen-year and nearly $3 billion effort.64 Today, the price for the sequencing of an entire human genome is under $5,000 and is continuing to fall.65 The NIH and other research institutions are striving to bring the cost of sequencing an
individual’s genome to $1,000 or less, increasing the availability of genetic sequencing to consumers.66 One private sequencing technology company, Illumina, recently announced that the company would begin producing
56

Research Portfolio Online Reporting Tools, Human Genome Project, NATIONAL INSTITUTES OF HEALTH,
at https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx (Jan. 6, 2015).
57
Jeantine E. Lunshof et al., Personal genomes in progress: from the Human Genome Project to the Personal Genome Project, DIALOGUES IN CLINICAL NEUROSCIENCE (Mar. 2010), available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181947/.
58
Id.
59
Understanding the Human Genome Project – A Fact Sheet, 8 NIH MEDLINEPLUS 15 (Spring 2013), at
http://www.nlm.nih.gov/medlineplus/magazine/issues/summer13/articles/summer13pg15.html.
60
Id.
61
Nat’l Human Genome Research Institute, supra note 42.
62
Id.
63
Understanding the Human Genome Project – A Fact Sheet, supra note 59.
64
Nat’l Human Genome Research Institute, supra note 42; Michael Malecek, Emerging Trends In Nucleic
Acids And Human Genome Work, LAW 360, (Dec. 18, 2012); Trevor Woodage, Gatekeepers and Goalposts: The Need for a New Regulatory Paradigm for Whole Genome Sequence Results, 11 NW. J. TECH. &
INTELL. PROP. 1 (2012).
65
Malecek, supra note 64; Palmer, supra note 5, at 483. (“[T]he cost of whole genome sequencing…is expected to dip below the thousand-dollar mark soon”).
66
See generally, Nat’l Human Genome Research Institute, supra note 42.
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a new system this year that could sequence the full human genome for less
than $1,000.67 Individualized analysis of a personal genome will lead to a
powerful tool of preventive medicine.68 This new form of personalized
health care will reshape preventative and diagnostic care to complement
each individual based on his or her unique genetic code.69 Full genomic
sequencing is not only important to individual patient care, but with the
ability to sequence possibly millions of people, researchers will be able to
truly understand how gene variants contribute to disease.70 This
knowledge can then be used to develop more effective treatments and
pharmaceuticals.71
The data researchers currently use comes from people who have
provided consent to the use of their genomes for projects such as the Human Genome Project and the Personal Genome Project.72 A controversy
arises with the use of information paid for personally by individual directto-consumer genetic testing consumers. There is a debate on whether such
personal genetic information should be available for use in supplemental
research and the level of consent that should be required.
Direct-to-Consumer Genomic Testing
With the completion of the Human Genome Project in 2003, the
interest in personal genetic information in the United States has increased
exponentially.73 It became clear that Americans wanted access to their
personal health blueprints, and as the cost of genetic testing plummeted,
the direct-to-consumer (DTC) genetics industry emerged to meet this demand.74 With several affordable choices available today, consumers can
select a DTC provider, order a test kit online, send in a saliva sample, and
then wait just a few weeks to gain access to the plethora of information
contained in their very own unique genome.75

67
Erika Check Hayden, Is the $1000 genome for real?, NATURE (Jan. 15, 2014) (“If there was any doubt to
if genomics would ever be able to reach the everyday man, at this price point and efficiencies it is absolute
certainty.” quoting Michael Schatz).
68
Understanding the Human Genome Project – A Fact Sheet, supra note 59.
69
Palmer, supra note 5, at 481.
70
Hayden, supra note 67.
71
Id.
72
See generally National Human Genome Research Institute, at www.genome.gov; (Jan. 7, 2016); Human
Genome Project, at www.report.nih.gov. (Feb. 18, 2015).
73
Schleckser, supra note 7, at 697.
74
Id.
75
Id.
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Traditional genetic testing is done through a healthcare provider.76
A patient who wants to be tested for disease risks or to determine if he or
she is a carrier of a particular gene must see a doctor.77 The doctor will
determine which tests, if any, are appropriate, collect samples, and send
those samples to a laboratory.78 The laboratory returns the results to the
doctor, who then interprets the results for the patient.79 However, DTC
tests take the doctor out of the equation and gives control directly to the
patient.80
To some, most prominently regulation agencies, the absence of the
learned intermediary has potentially unsafe consequences, with DTC companies essentially providing unregulated medical diagnoses.81 Many of the
commercial providers primarily market to people seeking to learn about
their ancestry, but most of the recent controversy has been on those DTCs
that provide health-related genomic services.82 The International Society
of Genetic Genealogy currently lists twenty-five commercial testing providers.83 Of those twenty-five providers, only two currently list “health”
as a purpose for the genetic testing services.84 Largely due to the threats of
tough regulation, companies that emerged as leaders in the late 2000s such
as deCODEme, Navigenics, and Pathway Genomics have widely fallen off
the map.85 Under pressure by the FDA in 2010, Pathway Genomics and
Navigenics quickly eliminated the customers’ ability to order tests without
physician involvement.86 Then in 2012, both deCODEme and Navigenics
76

Id. at 698.
Id. at 698-99.
78
Id.
79
Id. at 699.
80
Id.
81
See infra notes 111-16 and accompanying text.
82
Palmer, supra note 5, at 483.
83
List of DNA testing companies, at http://www.isogg.org/wiki/List_of_DNA_testing_companies. (Nov.
11, 2015).
84
Id. 23andMe and Gene by Gene are the two companies listed with “health” still listed as a function of the
company. 23andMe has since ceased offering genetic reports due to FDA intervention. See Warning U.S.
FOOD AND DRUG ADMINISTRATION, supra note 2. See also Anne Wojcicki, 23andMe Provides An Update
Regarding FDA’s Review, 23ANDMEBLOG (December 5, 2013), http://blog.23andme.com/news/23andmeprovides-an-update-regarding-fdas-review/.;. INTERNATIONAL SOCIETY OF GENETIC GENEALOGY WIKI,
supra note 83; Schleckser, supra note 7, at 700.
85
Schleckser, supra note 7, at 700; see infra notes 110-25 and accompanying text.
86
Schleckser, supra note 7 at 700; See also Dan Vorhaus et al., DTC Genetic Testing and the FDA: Is
There an End in Sight to the Regulatory Uncertainty?, GENOMES UNZIPPED (June 16, 2011),
http://www.genomesunzipped.org/2011/06/dtc-genetic-testing-and-the-fda-is-there-an-endin-sight-to-theregulatory-uncertainty.php#more-3681; The FDA sent Pathway Genomics a letter in 2010 stating that its
Genetic Health Report was a medical device under the Act requiring FDA approval. U.S. Food and Drug
Administration, Letter to Pathway Genomics Corporation Concerning the Pathway Genomics Genetic
Health
Report.
5/10/10,
MEDICAL
DEVICES,
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm211866.htm. See infra note 123.
77
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were acquired by biotech companies and left the DTC market.87 As a result, the genetic testing company 23andMe emerged as the undisputed
leader in the DTC market. 88
23andMe offers their genomic testing services for $99.89 Consumers enroll via the website and purchase a DNA kit through the online
store.90 The 23andMe kit arrives with detailed instructions.91 Following
the instructions, customers spit two milliliters of saliva into a collection
tube through an attached funnel.92 Closing the lid of the funnel releases
the stabilization buffer into the collection tube.93 Then the funnel is removed, a cap attached, and the tube is ready for shipping.94 The customer
packs her sample into the prepaid box and drops it into a mailbox.95
The saliva sample is sent to and processed by a clinical laboratory.
96
The lab typically genotypes over one million SNPs and then “presents
this SNP information to the consumer in the form of a personalized genomic report, which includes disease risk estimates, . . . pharmacogenomic
information, carrier status for [select] heritable diseases, and . . . ancestry
information.”97 23andMe results are typically available four to six weeks
after [the] customer’s kit arrives at the laboratory.98 23andMe provided
results for over 200 conditions ranging from earwax type and bitter taste
perception to risk for Alzheimer’s disease and multiple sclerosis.99
87
Id.; Pathway Genomics today is still considered a DTC testing company even though it requires physician permission because it provides the information directly to the customer through its web portal.
Schleckser, supra note 7, at footnote 30.
88
Id.
89
How it works, 23ANDME, https://www.23andme.com/howitworks/.
90
Id.
91
Providing
your
saliva
sample,
23ANDME,
https://customercare.23andme.com/hc/enus/articles/202904530-Providing-your-saliva-sample.
92
Id.
93
Id.
94
Id.
95
Id.
96
Palmer, supra note 5, at 483-84; Schleckser, supra note 7, at 701.
97
Palmer, supra note 5, at 484. It is important to note that direct-to-consumer genetic tests like 23andMe
are only examining predetermined locations on the genome – the SNPs – that are associated with particular
traits. See Schleckser, supra note 7, at 701. In contrast, whole genome sequencing determines the precise
sequence of all three billion base pairs in the individual genome. Id. Genotyping is currently much more
cost effective but does have its disadvantages. Id. at 702. Since not all genetic variation takes the form of
SNPs, genotyping misses many genetic variants present throughout the genome. Id. It cannot detect rare
mutations, such as deletions or duplications of DNA, and in some populations, a given SNP may not be an
accurate marker for a nearby mutation. See Palmer, supra note 5, at 484. As the cost of full genome sequencing continues to fall, genetic tests genotyping only SNPs will fall out of favor but until then the ability
to access even a fraction of one’s genetic information for a reasonable price will still be attractive to consumers.
98
Schleckser, supra note 7, at 701.
99

Id. at 703; Health Risks, 23ANDME, https://www.23andme.com/you/health/risk/.
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23andMe used only those SNPs that were clinically validated in two or
more research studies and agreed to collaborate with other DTC companies to develop a consensus in how to calculate disease risk predictions.100
Each test listed in the health report is categorized according to the degree
of scientific support for the relevant genetic association.101 The tests with
the highest confidence are established research reports.102 They have been
involved in multiple studies with over 750 participants or have the consensus of the scientific community.103 Tests with less confidence are listed as
being in the preliminary research stage and have been involved in one
study of more than 750 participants.104 These tests are based on peerreviewed findings that have yet to be confirmed by the scientific community.105 Tests with low confidence are also included and are described as
preliminary research with the studies done involving less than 750 participants.106 Test results are presented graphically and numerically, displaying the customer’s risk as a percentage and comparing that risk to the average risk of the population.107 Similarly, drug response results are listed
according to scientific validity and list the customer’s sensitivity to each
drug compared to the average population.108 A customer can also download his or her raw data into a text file, which includes each genotype at
the approximately one million SNPs tested.109
Efforts to Regulate DTC Testing
The current state of DTC regulation is messy and unclear.110
Three federal agencies that play a role in the regulation of genetic tests are
Centers for Medicare and Medicaid Services (CMS), the Food and Drug
Administration (FDA) and the Federal Trade Commission (FTC).111 CMS
regulates all clinical laboratories performing genetic testing, ensuring their
compliance with Clinical Laboratory Improvement Amendments of 1988

100

Palmer, supra note 5, at 485.
Schleckser, supra note 7, at 703; Health Risks, supra note 99.
102
Schleckser, supra note 7, at 703.
103
Health Risks, supra note 99.
104
Id.
105
Schleckser, supra note 7, at 703.
106
Health Risks, supra note 99.
107
Schleckser, supra note 7, at 703.
108
Drug Response, 23ANDME, https://www.23andme.com/you/health/drug_response/.
109
Schleckser, supra note 7, at 703.
110
Id. at 705 (“Regulation of DTC genetic testing is a hodgepodge at best”).
111
Id.; NAT’L HUMAN GENOME RESEARCH INSTITUTE, supra note 20. The FTC’s authority relates to how
genetic tests are advertised. Id.
101
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(CLIA).112 The FDA has the broadest authority to regulate genetic tests as
medical devices.113 Under the Federal Food, Drug and Cosmetic Act (the
Act), the FDA has the power to review all new medical devices for safety
and effectiveness.114 A medical device is defined in section 201(h) of the
Act as a device intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease.115 The
degree of FDA oversight of a genetic test is based on its intended use and
the risks posed by an inaccurate test result.116 The agency categorizes
medical devices into three separate classes: class I for low risk products,
class II for moderate risk products, and class III for tests requiring the
greatest level of scrutiny.117 Class III devices require premarket approval
by the FDA.118
In 2010, the FDA announced that it planned to regulate genetic
testing, citing concerns in the growing separation between the commercial
laboratories doing the testing and the physicians ordering the test.119 There
were growing concerns that DTC genetic tests were medically unproven,
meaningless, and misleading for consumers.120 Congress and the Government Accountability Office (GAO) also released reports that voiced
concerns on the deceptive practices of DTC genetic tests, referring to the
tests as “misleading and of little or not practical use.”121 That same year,

112

Id. Congress passed CLIA in response to concerns about the quality of clinical laboratory testing.
Woodage, supra note 64, at 4. CLIA allowed CMS and CDC to implement standards for laboratory certification. Id. These standards focus on quality control and quality assurance mechanisms with laboratories
rather than the concerns about the clinical uses of test results. Id.
113
Regulation of Genetic Tests, supra note 20.
114
Id.
115
21 U.S.C. 321(h); FD&C Act 201(h).
116
Regulation of Genetic Tests, supra note 20.
117
Id.; See also 21 U.S.C. 360c (As device class increases from Class I, to Class II, to Class III, the regulatory controls also increase); Regulatory Controls, FOOD AND DRUG ADMINISTRATION,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/
ucm2005378.htm (June 26, 2014) (Class I devices are subject to the least regulatory control, and Class III
devices are subject to the most stringent regulatory controls. Id. An example of a Class I device is a manual toothbrush). Compare with How to Study and Market Your Device, FOOD AND DRUG ADMINISTRATION,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm
, (Feb. 27, 2015) (An example of a Class II device is a non-invasive blood pressure monitors. Id. A heart
value is classified as a Class III device). Id.
118
21 U.S.C. 360c(a)(1)(C).
119
Regulation of Genetic Tests, supra note 20. .
120
Id.
121
Id.; Palmer, supra note 5, at 493; (The 2010 report by the GAO is entitled “Direct-to-Consumer Genetic
Tests: Misleading Test Results are Further Complicated by Deceptive Marketing and Other Questionable
Practices” and identified ten egregious examples of deceptive marketing). Kevin de Leon, Senate Appropriations Committee Fiscal Summary (May 20, 2013) http://leginfo.ca.gov/pub/13-14/bill/sen/sb_02010250/sb_222_cfa_20130520_092108_sen_comm.html; DIRECT-TO-CONSUMER GENETIC TESTS:
Misleading Test Resulting Are Further Complicated by Deceptive Marketing and Other Questionable Prac-
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the FDA began sending warning letters to DTC companies, notifying them
that their services were medical devices subject to FDA regulation.122 The
first such letter was sent to Pathway Genomics.123 Pathway had recently
announced a marketing partnership with the drugstore chain Walgreens but
the letter quickly caused Walgreens to back out and Pathway soon moved
to a physician consent based business model.124 Twenty letters were sent
out in 2010 to DTC testing companies, including 23andMe.125
Either in spite of or in defiance to the FDA, 23andMe “pressed on
under the shadow of possible regulation” until July 2012 when it decided
to seek regulatory approval.126 23andMe announced that it submitted the
first set of 510(k) documentation to the FDA.127 The application provided,
according to 23andMe, a detailed description of the Person Genome Service, extensive data supporting the performance of the technology, and
comprehensive discussion of the science supporting the information presented to customers about their genetics and its impact on health.128
23andMe remained committed to the belief that consumers have a fundamental right to their personal genetic data.129 Dissatisfied with the lack of
cooperation by 23andMe, the FDA reiterated its policy that providing what
tices, U.S. GOVERNMENT ACCOUNTABILITY OFFICE (July 22, 2010), available at
http://www.gao.gov/products/GAO-10-847T.
122
Schleckser, supra note 7, at 706.
123
Palmer, supra note 5, at 493. See supra note 86.
124
Id.
125
Schleckser, supra note 7, at 706.
126
Id. at 707.
127
23andMe Takes First Step Toward Clearance, 23ANDMEBLOG (July 30, 2012),
http://blog.23andme.com/news/23andme-takes-first-step-toward-fda-clearance/; See also Section 510(k) of
the Food, Drug and Cosmetic Act requires device manufacturers to notify the FDA of their intent to market
a medical device at least 90 days in advance. 510(k) Clearances, U.S. FOOD AND DRUG ADMINISTRATION
(Jan.
13,
2015),
at
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/510k
Clearances/; 21 U.S.C. 360(k); FD&C Act 510(k). Anyone who intends to market in the U.S. a Class I, II,
or III device for human use, for which a Premarket Approval is not required, must submit a 510(k) submission to the FDA. Premarket Notifications 510(k), U.S. FOOD AND DRUG ADMINISTRATION (Feb. 24, 2014),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketS
ubmissions/PremarketNotification510k/default.htm#when. A 510(k) is a premarket submission made to the
FDA to demonstrate that the device is substantially equivalent to another legally marketed device. Id. That
is, the device to be marketed must be at least as safe and effective as the comparable device currently on the
market. Id. In the Warning Letter sent to 23andMe, the FDA indicated that the 510(k) mechanism is not
appropriate because there are no substantially similar approved tests already on the market. See Warning
Letter, supra note 2; Gary Marchant, The FDA Could Set Personal Genetics Rights Back Decades, SLATE
(Nov.
26,
2013
12:39
PM),
http://www.slate.com/articles/technology/future_tense/2013/11/_23andme_fda_letter_premarket_approval_
requirement_could_kill_at_home_genetic.html. The FDA determined the 23andMe must instead seek premarket approval or de novo classification of its tests. Id. What The FDA Decision Means For 23andMe
Customers, infra note 147.
128
23andMe Takes First Step Toward Clearance, supra note 127.
129
Id.
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looks like disease diagnoses makes 23andMe’s service a medical device
and thus is subject to FDA approval.130 The FDA ordered the company to
discontinue marketing the Personal Genome Service.131
As of December 5, 2013, 23andMe ceased offering new customers
access to health-related genetic tests pursuant to an FDA’s directive.132
Customers who had purchased kits before November 22, 2013 continue to
have access to health reports previously provided by 23andMe, but any
DNA kits purchased after that date have access only to ancestry-related information and their raw data without interpretation of that data by
23andMe.133 In a letter dated November 22, 2013 the FDA warned
23andMe that the company was marketing its Personal Genome Service
without marketing clearance or approval in violation of the Act.134 The
FDA has classified the Saliva Collection Kit as a medical device within
the meaning of the Act because it is intended for use in the diagnosis of
disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the
body.135 The FDA quotes language from the 23andMe website and says
that most of the intended uses for the Personal Genome Service listed on
the website, for example health reports providing “health risks,” “carrier
status,” “drug response,” and “first step in prevention” that enables users
to “take steps toward mitigating serious diseases” are medical device uses
under the Act.136 These uses require premarket approval from the FDA.137
The FDA cites some of these uses as particularly concerning because of
the potential health consequences.138 In particular the FDA believes that
assessments for the BReast CAncer susceptibility gene (BRCA)-related
genetic risk and drug responses could lead a patient to take unnecessary
drastic measures based on a false positive or fail to recognize an actual risk
that may exist based on a false negative.139 The FDA says that it has no
assurance that the company has analytically or clinically validated the Per130
Id. (The FDA also did not care for 23andMe’s plan for an expanded marketing effort, including a
planned television ad campaign). Robert Hof, Seven Months After FDA Slapdown, 23andMe Returns With
New
Health
Report
Submission,
FORBES
(June
20,
2014),
http://www.forbes.com/sites/roberthof/2014/06/20/seven-months-after-fda-slapdown-23andme-returnswith-new-health-report-submission/.
131
Warning Letter, supra note 2; Hof, supra note 130.
132
Wojcicki, supra note 84.
133
Id. November 22, 2013 is the date of the warning letter sent by the FDA.
134
Warning Letter, supra note 2.
135
Id.
136
Id.
137
Id.
138
Id.
139
Warning Letter, supra note 2.
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sonal Genome Service for its intended uses and thus must discontinue
marketing the PGS until it receives the proper authorization from the
agency.140
The FDA and 23andMe came to an agreement that the genetic testing company could continue to sell the test on the condition that it provided only raw genetic data and ancestry information, not health reports.141
With this discontinuance in service, people have few options to obtain a
health report based on their genetic information.142 In essence, this sort of
regulation has caused pure DTC testing to cease to exist.143 23andMe
agreed to go through the long and arduous FDA approval process.144
However, this has been a significant step backward in an individual’s control of their genetic information and a step toward FDA regulation of genetic information. The agency’s designation of 23andMe’s service as a
medical device inhibits the consumer from accessing his or her own genetic information without the permission of a learned intermediary.145 Until
23andMe can gain approval for each of its more than 200 genetic tests,
consumers are left with little choice.146
III. ANALYSIS
The FDA and associated regulatory agencies need to develop a
comprehensive regulatory plan that addresses the issues it raises regarding
consumer safety and privacy without unnecessarily restricting an individual’s right to his personal information and trampling a potentially vastly
useful and significant DTC genetic testing market. The first section argues
140

Id.
Wojcicki, supra note 84
142
Promethease – Genetic Health Information Alternative, DNAEXPLAINED – GENETIC GENEALOGY (Dec.
30,
2013),
http://dna-explained.com/2013/12/30/promethease-genetic-health-information-alternative/.
(Third parties offering interpretive reports such as Promethease have emerged in the market to fill this new
void. At Promethease people can upload the text file obtained from any DTC testing service including
23andMe. They will process the raw data and provide the customer with a report that is available for
download from the server).
143
Schleckser, supra note 7, at 705.
144
Wojcicki, supra note 3.
145
Schleckser, supra note 7, at 707.
146
Anne Wojcicki, A Note to Our Customers Regarding the FDA, 23ANDME BLOG (Dec. 23, 2015),
http://blog.23andme.com/news/a-note-to-our-customers-regarding-the-fda/. (On February 19, 2015, the
FDA granted authorization to 23andMe to market the Bloom Syndrome Carrier Status report, the first such
authorization granted to any DTC genetic test. This gives 23andMe a regulatory framework for future submissions. Because 23andMe successfully gained authorization from the agency, it may be able to submit
some future submission through the standard 510(k) pathway as opposed to the much more stringent de
novo review). What The FDA Decision Means For 23andMe Customers, 23ANDME BLOG (Feb. 19, 2015),
http://blog.23andme.com/news/what-the-fda-decision-means-for-23andme-customers/.
141
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for the necessity of freely accessible genetic information and its benefits to
both individual consumers and patients and society as a whole because its
promise to transform healthcare as we know it. The next section then explores the concerns about DTC genetic testing put forth by both regulatory
agencies and legislators and attempts to explain why many of these concerns are both shortsighted and heavy-handed, largely doing more to stifle
the genetic testing industry rather than protect consumers. Nevertheless,
valid concerns do exist in the DTC genetic testing landscape that can be
addressed in such a way as to both protect consumers and promote scientific innovation, benefiting all of society. Lastly, I argue that the Genomics and Personalized Medicine Act (GPMA), originally introduced in
2006, is a suitable starting point for legislation aiming to protect consumers while expanding and accelerating beneficial genomics research.
The Need For Open Accessibility of Genetic Information
To use whole genome sequencing to uncover changes in DNA that
underlie disease, scientists and clinicians need access to whole genome sequence data from many individuals.147 Continued advances in healthcare
depend on large numbers of individuals willing to share their data for research purposes.148 Additional health and demographic information on
each individual further aid researchers in making connections between variations in whole genome sequence data and specific diseases.149 Public sequencing projects like the Personal Genome Project rely on public participation for their success.150 The PGP’s model is based on open consent and
public data access to further human genomic research.151 Data sets and
tissue samples from the project are made publicly available with minimal
or no access restrictions and can generally be transferred to outside research studies to be utilized by and combined with data from third parties.152 This organized effect is essential to the success of genomic research.153
The DTC genetic testing company 23andMe is not just a place for
customers to learn about their own ancestry and genetic predisposition to
147

Presidential Commission for the Study of Bioethical Issues, Privacy and Progress in Whole Genome
Sequencing, page 16 (2012),
148
Id.
149
Id.
150
Jeantine E. Lunshof et al., Personal genomes in progress: from the Human Genome Project to the Personal Genome Project 12(1) DIALOGUES IN CLINICAL NEUROSCIENCE 47, 47-60 (Mar. 2010).
151
Id.
152
Id.
153
Id.
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diseases, it has also become one of the largest databases of personal genetics information in the world.154 23andMe has a substantial research arm
and has done significant medical research with the database of genetic information it has built.155 They are also able to offer the genetic data of
700,000 people to researchers and pharmaceutical companies to conduct
large-scale medical studies that would normally take months or years to
solicit enough volunteers.156 23andMe offers customers the opportunity to
participate in genetic research at the time they purchase the testing kit.157
23andMe asserts that its customers who consent to research contribute to
over 230 studies.158 The company has identified hundreds of new genetic
associations.159 The more innocuous include whether a person is likely to
sneeze when looking at a bright light or whether a person can smell asparagus in his urine to.160 More promising research includes the company’s
recent findings on Parkinson’s disease.
A study with more than 10,000 participants has identified two new
genetic associations for the disease.161 This led to 23andMe’s first patent
in May 2012 entitled “Polymorphisms Associated With Parkinson’s Disease.”162 The patent relates to the discovery of a variant in the SGK1 gene
that may be protective against Parkinson’s disease in individuals who carry the rare risk-associated LRRK2 G2019S mutation.163 In its announcement of the patent, 23andMe emphasizes its belief that patents should not
be used to obstruct research and maintains that obtaining a patent is an important step in ensuring its genetic breakthroughs translate into real-world
benefits.164 Patents are important for biotechnology or pharmaceutical
companies as they provide assurance for the large financial investment required in the resource-intensive process of drug development.165 23andMe
goes on to say that its patent will not prevent other entities from accessing
the genetic data or its interpretation specific to its patents.166 Third parties
154

Heather Somerville, 23andMe aims to be Google for genetic research, SAN JOSE MERCURY NEWS Sept.
6, 2014. .
155
23andMe, Get involved in a new way of doing research, at, https://www.23andme.com/research/.
156
Somerville, supra note 154.
157
23andMe, supra note 155.
158
Id.
159
Id.
160
Charles Seife, 23andMe Is Terrifying, but Not for the Reasons the FDA Thinks (Nov. 27, 2013) at
http://www.scientificamerican.com/article/23andme-is-terrifying-but-not-for-reasons-fda/.
161
23andMe, supra note 155.
162
Anne Wojcicki, Announcing 23andMe’s First Patent, 23ANDMEBLOG (Mar. 28, 2012), at
http://blog.23andme.com/news/announcements/announcing-23andmes-first-patent/.
163
Id.
164
Id.
165
Id.
166
Id.
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can continue to use the genetic information without licensing fees, furthering their stated belief that meaningful research based genetic information
is their primary mission.167
Concerns in the DTC Genetic Testing Industry
Concerned with the privacy of individual participants, recent state
legislation has attempted to curb the wide availability of this information.168 Several states have attempted to enact legislation pertaining to
the privacy of genetic information.169 For example, the Genetic Information Privacy Act in California proposed by California State Senator
Alex Padilla attempts to regulate what DTC companies can and cannot do
with the genetic information of its customers.170 Similar bills have passed
in other states, including Illinois, but the range of protections differs from
state to state.171 California’s proposed bill is of particular interest because
there is currently no protection of genetic privacy outside of the health
care system and the booming biotech industry in the state is vocal about
how this type of legislation could slow the progress of research and clinical trials.172 The bill addresses concerns over DTC genetic testing companies that allow consumers to submit genetic samples in order to test for
genetic disorders, obtain ancestral information, or participate in research
studies.173
Currently, the federal Health Insurance Portability and Accountability Act (HIPAA) protects the genetic and personal health information of
167

Id.
Jessica Shugart, California bill would prevent genetic-testing firms from using surreptitiously obtained
DNA, SAN JOSE MERCURY NEWS (May 23, 2013).
169
Id. Over 30 states have some sort of laws in place providing protection against the collection or sharing
of genetic data. Id. The laws range from protecting the privacy of health-related genetic information to treating all DNA as private property. Id. Specifically, 27 states
require consent to disclose genetic information. Genetic Privacy Laws, National
Conference of State Legislatures, http://www.ncsl.org/research/health/geneticprivacy-laws.aspx (Jan. 2008). Five states explicitly define genetic information as
private property. Id. Four states mandate individual access to personal genetic information. Id. Nineteen states have established penalties, civil and criminal and in
some cases both, for violating genetic privacy laws. Id.
170
Id.; Senator Kevin de Leon, Senate Appropriations Committee Fiscal Summary, Bill Analysis (January
23, 2014); California Senate Bill 222 and Senate Committee Reports, available at
http://leginfo.ca.gov/pub/13-14/bill/sen/sb_0201-0250/sb_222_cfa_20140123_091418_sen_comm.html;
California Senate Bill 1267 and Senate Committee Reports; Chandi Abeygunawardana, Governing The
Code Of Life: Calif.’s DNA Privacy Bill, LAW 360 (June 6, 2012).
171
Shugart, supra note 168. See also Genetic Privacy Laws, supra note 169.
172
Shugart, supra note 168; Helen Shen, California considers DNA privacy law, NATURE (May 18, 2012),
http://www.nature.com/news/california-considers-dna-privacy-law-1.10677.
173
Kevin de Leon, Senate Appropriations Committee Fiscal Summary (May 20, 2013),
http://leginfo.ca.gov/pub/13-14/bill/sen/sb_0201-0250/sb_222_cfa_20130520_092108_sen_comm.html.
168
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patients but Senator Padilla maintains that the laws do not protect people
against companies outside the health care system.174 The Senate Appropriations Committee analysis of Senator Padilla’s bill cites the GAO report
that identifies deceptive marketing practices and misleading test results.175
If passed, the bill would prohibit any person from “obtaining, analyzing,
retaining, or disclosing genetic information without the written authorization of the individual to whom the information pertains” under the threat
of civil and criminal penalties.176 The bill includes exceptions such as for
a hospital, laboratory, or physician carrying out court-ordered tests, a licensed health care professional, and any person that is already required to
comply with HIPAA.177 DTC companies are specifically excluded from
the exhaustive list of exemptions.178
The University of California and other major research universities
argue that these exceptions do not go far enough and could have a costly
and damaging effect on research.179 The university wrote a formal letter to
the California legislature objecting to the bill.180 Under the proposed legislation, an individual’s genetic information may only be used by individuals
specifically named on a consent form and only for purposes given on the
consent form.181 A genomic dataset could not be re-used in separate experiments or be made available to third-parties for further research.182 Researchers must either destroy the data after each study or obtain new consent from individual participants, an infeasible task for studies involving
thousands of subjects.183
Geneticist David Segal, associate director of genomics at the University of California, Davis, believes such requirements could seriously
hinder genomic research.184 By being forced to re-obtain consent, California universities would essentially be barred from doing such large genomic
studies.185 The university estimates the provisions of the bill could increase central research and hospital administrative costs approximately
$40 million per year.186 The costs result from the increased workload as174

Shugart, supra note 168.
Kevin de Leon, supra note 170.
176
Id.
177
Kevin de Leon, supra note 173.
178
Id.
179
Shugart, supra note 168.
180
Shen, supra note 172.
181
Id.
182
Id.
183
Id.
184
Id.
185
Id.
186
Kevin de Leon, supra note 173.
175
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sociated with obtaining authorizations for research not covered by the exceptions enumerated in the bill.187
The University of California is also concerned that the state’s biomedical industry could be put at a distinct competitive disadvantage for
public and private research grants.188 To the extent research involving genomic data could become more difficult to conduct due to the added level
of consent, financiers could look to other states with less red tape.189 A reduction in research grants could result in a loss of millions of dollars in research funding for institutions within the state.190 Supporters of the bill
maintain that the bill does not prevent institutions from doing research and
that it simply adds a level of consent but the added level of consent is
over-burdensome.191 University of California policies governing human
research already require informed consent when using genomic data.192
Genetic information is also typically identified by number rather than by
an individual’s name.193 Under the bill, even anonymous data would require re-authorization for re-use.194 The first attempt to pass similar legislation stalled in 2012 in the Appropriations Committee.195 The new version of the bill was introduced in February 2013 and is currently pending
in the Senate.196
23andMe, a California based company, has similar concerns to the
University of California and other research institutions as to the detrimental effects of the genetic privacy bill.197 23andMe requires customer
consent for research participation.198 Research participation is an opt-in
choice during the kit registration process and customers can opt-out of future research at any time through his account.199 The consent forms and
privacy policy clearly state that its customers’ genomic information is used
for research by 23andMe and may be disclosed to third parties for outside
187

Id.
Shugart, supra note 168; Shen, supra note 172.
189
Kevin de Leon, supra note 173.
190
Id.
191
Shen, supra note 172.
192
Id.
193
Id.
194
Id.
195
Shugart, supra note 168.
196
S.B. No. 222. Complete Bill History, available at http://leginfo.ca.gov/pub/13-14/bill/sen/sb_02010250/sb_222_bill_20140203_history.html; See also Washington State Legislature, at Overview of the Legislative Process, http://www.leg.wa.gov/legislature/Pages/Overview.aspx. The bill can then be reintroduced and retained in its present position. Id. At this time it does not seem that the bill has been reintroduced.
197
Shugart, supra note 168.
198
See generally Get involved in a new way of doing research, supra note 155.
199
Id.
188
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research studies.200 23andMe explains that basic research consent means
that the customer’s genetic and self-reported information may be used in
an aggregated form, stripped of identifying registration information for
peer-reviewed scientific research.201 The company may disclose individual-level personal information to a third party only through an additional
level of consent given by the customer.202 The customer can choose to
have his DNA sample discarded to further ensure his privacy.203 Customers also have the option of simply receiving their raw genetic data with no
analysis.204 They can then take that raw data file to alternative companies
such as Promethease.205 Promethease will process the raw data and then
the raw data file is deleted within 24 hours of completion of the health report, providing additional security to those that wish to receive their health
report but not to share their genetic information.206
Individuals who freely give their consent to companies such as
23andMe or public projects such as the Personal Genome Project and wish
to contribute to the beneficial research taking place should not be prohibited from doing so. Senator Padilla cites concerns with specific genetic testing companies that make no attempt to discourage customers from secretly
sending in another’s genetic sample.207 The Illinois based company
EasyDNA encourages customers to send “discreet samples” such as hair,
clothing, or cigarette butts when it is not possible to directly obtain sample
from the individual to be tested.208 Companies that aim to surreptitiously
obtain DNA for nefarious reasons should be prohibited from doing so
through regulation but said regulation should not impede those doing beneficial research or hinder individuals’ ability to discover and use their own
genomic data for their benefit.209 23andMe requires that the person submitting the DNA sample has legal authorization to do.210 Although all
consent forms are filled out online, the testing kit requires eight milliliters
of saliva.211 A sample of that size usually takes a customer five to ten
minutes to gather, greatly minimizing the likelihood that amount of saliva
200

23andMe, Privacy Statement, (Dec. 7, 2015), https://www.23andme.com/legal/privacy/.
Id.
202
Id.
203
Id.
204
Get involved in a new way of doing research, supra note 155; Promethease privacy, SNPEDIA, (Mar. 25,
2014), at http://www.snpedia.com/index.php/Promethease/privacy
205
Promethease privacy, supra note 204.
206
Id.
207
Shugart, supra note 168.
208
Id.
209
Id. at 3. (discussing research concerns in light of potential regulation).
210
Id.
211
Id.
201

18#1_WASHBURN REVISED.DOC (DO NOT DELETE)

22

DEPAUL JOURNAL OF HEALTH CARE LAW

3/1/16 11:50 AM

[VOL. 18.1:1

could be secretly collected from another. 23andMe does not perform paternity or infidelity testing.212 There needs to be a distinction between genetic testing obtained by individuals that wish to gain knowledge about
their personal health and predisposition to cancer, diabetes, Parkinson’s
and a host of other diseases and the more deceitful uses of genetic testing
such as paternity testing without consent and “infidelity testing” in which
the underwear of an allegedly unfaithful partner is secretly tested for foreign genetic material.213
Immediate Concerns for the DTC Genetic Testing Consumer
Many opponents of public access to personal genetic data, including the FDA, cite concerns about the misuse of this data ranging from the
plausible to fanciful.214 The FDA in particular is concerned that physicians have been removed from the equation and consumers now have direct access to their genetic information straight from the testing facility.215
The FDA believes that marketing directly to consumers can increase the
risk to the consumer because of the possibility patients may make a decision that adversely affects their health based on the information received
from genetic reports.216 This stems from the FDA’s patent mistrust of the
accuracy of genetic tests being offered to consumers through DTC testing.217
The FDA has a legitimate concern in companies making high-risk
claims to their customers such as their risk for cancer or their likelihood of
responding to a specific drug.218 Companies certainly should not be making arbitrary determinations or allowing customers to rely on false or misleading marketing to make consumers believe tests are more reliable than
they actually are. However, this concern should not bar consumers from
gaining access to their genetic information without the consent of a physician. Rather the FDA, along with the other participating agencies, can alleviate this concern through proper regulation and strict enforcement for
212

Shugart, supra note 168.
Id.
Direct-to-Consumer Genetic Testing and the Consequences to the Public: Hearing before the Subcomm.
on Oversight and Investigations of the Comm. On Energy and Commerce, 111th Cong., 68-82 (.2d Sess.
2010) [hereinafter Prepared Statement by Shuren] (statement of Jeffrey Shuren, M.D., Dir. of the Center for
Devices and Radiological Health, Fed. Drug Admin.) (describing the potential effects of direct-to-consumer
testing).
215
Id.
216
Id at 79.
217
Id.
218
Id.
213
214
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companies not in compliance. The FDA believes that giving this type of
information directly to the consumer can cause the consumer to make a
rash decision such as stopping or changing the dose of a medication or
continuing an unhealthy lifestyle.219 To reach such a conclusion is drastic
and farfetched. This is especially clear in the BRCA-related genetic risk
example the FDA likes to use in its Warning Letters.220 The FDA is concerned that consumers that receive a false positive (the genetic test showed
the presence of a BRCA1 or BRCA2 genetic mutation that can cause cancer) will take unnecessary measures such a prophylactic mastectomy,
chemoprevention or other “morbidity-inducing actions.”221 What the FDA
either fails to recognize and conveniently overlooks is that no consumer
who learns they do have mutations in either the BRCA1 or BRCA2 genes
is going to take “morbidity-inducing actions” without first consulting with
a physician. These types of drastic measures must be performed by trained
physicians and thus a doctor as an intermediary is still present in the process. A doctor retains the ability to relay information to the patient and
advise the patient on the reliability of such tests and the likelihood of false
positives. A doctor may even recommended a second test to confirm.
There is no reason to assume that a consumer cannot responsibly control
his or her health decisions after receiving a genetic report from a DTC genetic testing service.
The report from 23andMe is also informative to the consumer and
ensures the consumer understands the limitations of the report.222 The genetic test from BRCA1 and BRCA2 mutations is listed as an established
research report, a test with the highest confidence and support of the scientific community.223 However, the report goes on to explain that the BRCA
mutations covered in the report are only three of hundreds in the BRCA1
and BRCA2 genes that can cause cancer.224 The absence of the mutations
tested in the 23andMe genetic report does not rule out the possibility of
other mutations that increase the risk of the disease.225 Further, only five
to ten percent of breast cancers occur in women with a genetic predisposi219

Prepared Statement by Shuren, supra note 214.
Warning Letter, supra note 2.
Id.
222
Inherited
Conditions,
BRCA
Cancer
Mutations,
23andMe,
at
https://www.23andme.com/you/journal/brca/overview/.
223
Id.; See supra notes 101-03 and accompanying text.
224
Id. 23andMe provides data for only three specific cancer-associated mutations because these three mutations account for 80-90% of all hereditary breast and ovarian cancers cases in people with Ashkenazi Jewish ancestry. Id. A powerful predictive tool, about 50-60% of women who have one of these three mutations will develop breast cancer. Id.
225
Id. About one in eight women with one of the three mutations will still develop breast cancer.
220
221
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tion for the disease, usually due to mutation in either the BRCA1 or BRCA
2 genes.226 Many other factors can contribute to the likelihood of developing breast cancer including family history and environmental factors.227
Given the amount of information 23andMe provides, it is unlikely even a
false negative would cause a consumer to fail to take or continue to take
preventative measures in his or her healthcare.
Similarly, the FDA’s concern with consumers self-managing their
prescription medicine based on the drug response assessment is unfounded. Genetic reports on drug responses from 23andMe assess the likelihood
of a consumer’s sensitivity to certain prescription drugs.228 For example,
the 23andMe genetic report tests an individual’s sensitivity to the generic
drug warfarin.229 Warfarin is an anticoagulant used to treat and prevent
blood clots.230 Finding a patient’s optimal dose of this life-saving drug is
notoriously difficult.231 This kind of genetic information can help a doctor
determine the initial dose of the drug.232 The 23andMe report explains that
there are many genetic and non-genetic factors that can affect how the
body responds to warfarin.233 A doctor takes into account several other
factors including age, sex, weight, and diet when selecting the initial dose
of warfarin.234 Throughout the Warfarin Sensitivity Report, 23andMe instructs consumers to continue taking their medication as directed and
enunciates that the information should be used in consultation with their
physician.235
23andMe is an example of the way DTC genetic testing services
should be run. The model 23andMe established is the model the FDA
should emulate when designing regulations for future DTC testing companies. Their reports provide reliable information while responsibly disseminating that information to consumers. The ability of individuals to obtain
reports that include over 200 tests for under $100 is a valuable tool in the
226

Id.
Id.
23andMeDrug, supra note 108.
229
23andMe,
Drug
Response>
Warfarin
(Coumadin®)
Sensitivity,
available
at
http://www.23andme.com/you/journal/warfarin/overview/. An overview of the drug Warfarin (Coumadin®). This test is also based on established research, fully supported by the scientific community.
230
Id.
231
Id.
232
Id.
233
Id.
234
Id.
235
Id. (“If you are taking warfarin, keep taking it as directed by your doctor;” “Consult with a healthcare
provider about confirming the result of taking appropriate next steps;” “Do not use the information in this
report on its own to stop, start, or mark any changes to any current treatment without first consulting a
healthcare provided.”) Id.
227
228
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continuing healthcare revolution in the United States.236 The ability for
consumers to obtain such valuable information without the requirement of
a physician as an intermediary is essential to an individual’s ability to be
proactive about their own healthcare. Again, these reports are a tool people are using to reclaim control over their health. It is not to say that a
learned physician is not an important and vital part of the healthcare process. It is essential that the DTC genetic testing industry work in conjunction with the healthcare community to ensure maximum benefit to society.
Concerns with Public Access to Genetic Information
There are of course risks associated with the publication of an individual’s genetic data.237 Many of these risks can be mitigated through
the proper legislation including requiring strict privacy controls and strong
security practices. As risks are inherent in society though, some threats
will always remain. Both 23andMe and public genome databases like the
Personal Genome Project disclose these risks in its consent forms.238
Risks associated with public disclosure include adverse affects on the employment, insurance and financial well being due to discrimination based
on information discovered in a person’s genetic data.239 There is also a
possibility of a security breach wherein personal data, not intended to be
published, could become public. The possible scenarios for nefarious uses
of pubic data are boundless. Like an episode of CSI, some tech savvy offender could take a DNA sequence data and make synthetic DNA to plant
at a crime scene, implicating some oblivious participant in the crime.
Though these risks are real and should be addressed by the FDA
and other enforcement agencies, they pale in comparison to the benefits of
the availability of a large public database for research purposes. Each participate consents to these risks when he or she chooses to sign the consent
forms and publically share genetic data. Participants choose to share their
personal data in hopes of making meaningful scientific contributions. Because of individual participation, society as a whole reaps the benefits of
research and the resulting scientific advancement.
236

Health Risks, supra note 99; How it works, supra note 89.
Harvard Med. Sch., Personal Genome Project (updated Dec. 13, 2011) available at
http://www.personalgenomes.org/static/docs/harvard/PGP_Consent_Approved_02212013.pdf; 23andMe,
Research Consent Document, https://www.23andme.com/about/consent/.
238
Research Consent Document, supra note 237.
239
Id. at 13. (Such a risk has been addressed in the Genetic Information Nondiscriminatory Act (GINA).
GINA prohibits individuals from discrimination by health insurers or employers based on genetic information. 42 U.S.C. § 2000ff (2014). The law does not apply to the use of genetic information in all circumstances.
237
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Proposed Legislation Based on the GPMA
While there is a need for appropriate regulation to protect consumers and patients, there is an equally pressing need to avoid creating a system of oversight that would be an obstacle to the continued growth of personalized medicine.240 Encouraging the advancement of genomic research
while ensuring individuals are adequately protected from deceptive practices of genomic testing companies through regulation involves a delicate
balance. The Genomics and Personalized Medicine Act (GPMA) was
originally introduced in 2006 by then-Senator Barack Obama and was reintroduced in 2010 by Congressman Patrick Kennedy.241 Though the bill
died in committee,242 it was a promising start on regulation that would protect individuals but not stifle innovation. The bill aimed to strike a balance
between consumer protection and flexibility for companies and research
institutions.243 The bill’s stated purpose was “to secure the promise of personalized medicine for all Americans by expanding and accelerating genomics research and initiatives to improve the accuracy of disease diagnosis, increase the safety of drugs, and identify novel treatments, and for
other purposes.”244 The bill established an Office of Personalized
Healthcare (OPH) within the Department of Health and Human Services
(HHS).245 The responsibilities of the OPH include the coordination of
cross-agency activities and the collaboration with federal agencies and private entities to implement the GPMA initiatives.246 These initiatives include development of a strategic, long-term plan to advance research and
development in personalized medicine and personalized medicine products, and to clarify and simplify the regulation of products used for personalized medicine to ensure that guidelines are consistent.247 The OPH
would also recommend a clear delineation between the roles and responsibilities of the FDA and the CMS in regulation and enforcement of prod-

240
Dan Vorhaus, The Genomics and Personalized Medicine Act Returns to Congress, GENOMICS LAW
REPORT (August 24, 2010), available at http://www.genomicslawreport.com/index.php/2010/08/24/thegenomics-and-personalized-medicine-act-returns-to-congress/.
241
Id.
242
Presidential Commission for the Study of Bioethical Issues, supra note 147.
243
Vorhaus, supra note 240.
244
Genomics and Personalized Medicine Act of 2010, H.R. 5440, 111th Cong. (2D Sess. 2010)2d (May 27,
2010).
245
Id. at §101.
246
Id.
247
Id.
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ucts used for personalized medicine, including laboratory-developed
tests.248
The GPMA also specifically addresses direct-to-consumer genetic
249
testing.
The Act directs the CDC to work in conjunction with the FDA
and FTC to conduct an analysis of the public health impact of DTC marketing of genetic tests, analyze the validity of claims made in marketing
campaigns, and make recommendations to the OPH regarding the protection of the public from potential harm of DTC genomic tests.250 The Act
also directs the FDA to collaborate with the FTC to identify and terminate
advertising campaigns that make false, misleading, deceptive, or unfair
claims regarding the risks or benefits of products used for personalized
medicine.251
For this current version of the bill to become law, it would likely
require extensive revision as personalized medicine and the use of DTC
genetic testing has grown exponentially in the last four years. The topic of
consent should be addressed in terms of the use of genomic data in future
research. The Act should mandate informed consent agreements that allow for future research in advance of clear research objectives but maintain the right of an individual to opt out of the research at any time.252 The
FDA should be given clear guidelines as to the scope of its regulatory
power and its priorities in the DTC genetic testing realm to ensure that its
oversight is not counterproductive to the best interests of individuals and
society by hampering research efforts. Unlike in the California Genetic Information Privacy Act, civil and criminal penalties should only be available in situations of intentional testing or use of genetic information without
consent and other nefarious uses of genetic testing.
IV. IMPACT
Proper legislation and regulation of DTC genetic testing can help
to minimize various privacy concerns while allowing for the use of genetic
data to further research in drug therapies, disease prevention, disease
248

Id.
Id.
Id.
251
See Vorhaus, supra note 240 at 3. While this was addressed in the GAO report around the same time as
the introduction of the bill, the GAO’s investigation is frequently criticized for being an “unscientific snapshot” of the field of genomic testing.
252
Id. at 1..H.R. 5440. This language is contained in the GPMA in regard to obtaining consent for a proposed national biobank. A similar consent structure would work well for private biobanks.
249
250
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treatments and ultimately, to find genetic paths to cures.253 Last year saw
the first use of emergency genome sequencing to aid in direct treatment.254
Fourteen-year-old Joshua Osborn was rushed to the hospital with headaches, fever, and brain swelling so severe he was put in a medically induced coma.255 After weeks of testing and even a brain biopsy, the doctors
were no closer to discovering the cause of his illness.256 Then doctors decided they would run one more test using an experimental DNA technology and researchers’ newest genomic sequencing technique: nextgeneration sequencing.257 Doctors prepared samples of Joshua’s cerebrospinal fluid and sent the samples to researchers at the University of California, San Francisco for sequencing.258 After two days, the sequencers
determined the sequences of three million fragments of DNA present in
the boy’s samples.259 After removing the human DNA fragments, the remaining DNA was compared to sequencing data from the National Center
for Biotechnology Information, an online host of genomic databases
worldwide.260 Within just a few hours, the doctors discovered that Joshua’s cerebrospinal fluid contained DNA from a potentially lethal bacterium called Leptospira.261 While extremely difficult to discover, Leptospira is easily treated with penicillin and Joshua started to recover almost
immediately.262
Experts in the field are excited about the plethora of possibilities in
the field of genomic testing.263 “Diagnosis is a crucial step in treating illness but can also be the most difficult.”264 In many situations, doctors can
only guess at a diagnosis based on the symptoms and then run costly and
time-consuming tests to determine the cause of the problem.265 Though
further research is required, this case study shows DNA sequencing can be
253

Anne Wojcicki, A Note To Our Customers About The New Year, 23ANDMEBLOG (Jan. 12, 2015), at
https://blog.23andme.com/news/announcements/a-note-to-our-customers-about-the-new-year/.
254
Top
Genetic
Findings
of
2014,
23ANDMEBLOG
(December
26,
2014),
at
http://blog.23andme.com/news/top-genetic-findings-of-2014/; citing Carl Zimmer, In a First, Test of DNA
Finds
Root
of
Illness,
N.Y.
TIMES
(June
4,
2014),
available
at
http://www.nytimes.com/2014/06/05/health/in-first-quick-dna-test-diagnoses-a-boys-illness.html?_r=0. See
Michael R. Wilson et. al., Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing, 370
NEW ENG. J. MED. 2408 (2014).
255
Wilson, supra note 254 at 2408.
256
Zimmer, supra note 254.
257
Id.; See supra notes 49-51 and accompanying text.
258
Id.
259
Id.
260
Top Genetic Findings of 2014, supra note 254.
261
Zimmer, supra note 254.
262
Id.
263
Id.
264
Id.
265
Id.
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an immensely useful tool in diagnostics.266 Instead of performing multiple
tests to search for the pathogen, DNA sequencing can reveal the pathogen
immediately.267 Whether it is a virus, bacterium, fungus or parasite, just
one test is needed.268
This is just one example of the potential impact this may have on
the future of genetic testing and research. A Presidential Commission espoused this notion in its whole genome sequencing report stating that
“[w]hole genome sequencing offers the promise of tremendous public
benefit, and is expected to change substantially our ability to assess risk,
diagnose, and treat disease.”269 Scientists predict that whole genome sequencing research will promote a better understanding of the genetic factors that contribute to the overall health of individuals.270 Whole genome
sequencing will change how individuals manage their own health through
personalized medicine, allowing physicians to tailor treatments and manage the health of individuals based on their genetic profiles.271
The research conducted using publically available data also supports scientific entities that advance the common good by increasing economic opportunities.272 The U.S. government invested billions of dollars
in the Human Genome Project.273 This investment has generated $244 billion in personal income and $796 billion in overall economic impact.274
Taking data from just 2010, human genome sequencing projects and related research directly and indirectly generated over 300,000 jobs and $3.7
billion in tax revenue.275 In addition to the vast public benefit of genomic
research, the economic impact of promoting scientific innovation is also
significant. Ensuring this kind of impact continues to propagate throughout society should be a top priority of United States legislators and regulatory agencies.
V. CONCLUSION
The essence of the GPMA should be preserved: to secure the
promise of personalized medicine for all Americans. Regulation that pro266

Id.
Id.
268
Id.
269
Presidential Commission for the Study of Bioethical Issues, supra note 147, at 34.
270
Id. at 35.
271
Id.
272
Id.
273
Id.
274
Id. at 36.
275
Id.
267
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motes improving the accuracy of disease diagnosis, increasing the safety
of pharmaceuticals, preventing deceptive marketing practices, and ensuring consent is openly and voluntarily given while expanding and accelerating genomics research is in the best interesting of every person and societ

